Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laherradurin is a naturally occurring **acetogenin** isolated from *Annona macroprophyllata* that has been investigated preclinically as an anticancer agent, particularly in colorectal cancer. In the cited murine azoxymethane dextran sulfate sodium colorectal cancer model, laherradurin reduced tumor number and size, showed evidence of apoptosis induction, inhibited migration of HCT116 colon cancer cells in vitro, and appeared less toxic than cisplatin in that study. Its precise molecular target and mechanism of action have not been definitively established from the provided evidence, so it is best described as a natural product small molecule with experimental antineoplastic activity rather than a clinically developed targeted therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on laherradurin.